The Cardiovascular Research Technology (CRT) Meeting 2024 was held in Washington, D.C., USA from Ma£rch 9th to 12th. Siran Bio was honored to be invited to present the research findings o¥f SA016, a new drug for treating high blood pressure, at t∑he CRT conference. On March 10th, Dr. Yang Zhiwei, the founder of ✘Siran Bio, shared the non-clinical efficacy and safety of SA016 in Washington, which g₽arnered great attention and recognition from the industry.

The Cardiovascular Research Technology (CRT) Meetin g 2024 was held in Washington, D.C., USA from March 9th to 12th. Siran Bio was≥ honored to be invited to present the research findings ♣of SA016, a new drug for treating high blood pressure, at the CRT ®conference. On March 10th, Dr. Yang Zhiwei, the founder of☆ Siran Bio, shared the non-clinical efficacy and safety of SA016 in Washington, which garnered grea‌t attention and recognition from the industry.

SA016 is an siRNA drug that utilizes N-acetylgalactosamine (GalNAc) conjugation technology to tar♦get angiotensinogen (AGT) mRNA. It can suppress the expression of AGT protein, there≈by inhibiting the activity of the renin-angiotensin system (a key factor in the deve≥lopment of hypertension), achieving the goal of lowering blood pressureγ levels. This drug is primarily developed for the trea>tment of hypertension, and similar siRNA drugs like Zilebesir≤an have shown good antihypertensive effects in several Phase 2 clinical studies.

SA016 showed excellent activity in head-to-head studies with Zilebes iran both in vitro and in vivo. It demonstrated excellent AGT mRNA silencing effects in several i♠n vitro cell systems, including cell lines, mokey primary hepatocyt♠es, and human primary hepatocytes. In in vivo mouse models and crab-e♠ating macaque studies, SA016 showed excellent AGT protein inhibition and long-lasting e fficacy. Current data from crab-eating macaque studies indicate that SA016 can maintain activi×ty for three months without rebound after a single admini±stration. In spontaneous hypertensive crab-eating macaque models, SA016 showed e≠xcellent blood pressure control levels compared head-to-head with Zilebesiran. SA016 also showed su'perior safety in off-target studies in vitro and toxicologi♥cal studies in vivo.

This year's CRT meeting placed a high emphasis on hypertension. Medtronic and ₹Recor Medical used interventional treatment technolo✘gies to reduce signal transmission from renal nerves to the brain, which has a good long-term thera‌peutic effect on hypertension related to kidney disease.≥ Siran Bio's SA016 has excellent complementary and combinatio←n opportunities with these emerging technologies.

The research findings of SA016 mark the international recognition of Siran Bio's i♥nnovation in the cardiovascular field. We look forward to sharing our research progress with globa"l experts, achieving broader and deeper cooperation with the industry, and jointly promoting the ↑rapid entry of SA016 into clinical trials and the market to benefit a wide range of hypertensive pa&tients.

About CRT Meeting

The CRT conference in the United States is one of the world&#₹39;s leading conferences in interventional cardiology,focusing on progress and changes in the field§ of cardiovascular medicine. The annual CRT conference discusses new trial data,> explores evidence-based research, and showcases the late€st technologies that can be directly applied to clinical and academic practice.

About Siran Bio

Siran Bio was established in Suzhou Industrial Park in May 2022. It is a biot∑echnology company focused on the development of innovative siRNA drugs, co-founded by a top te÷am of scientists in the field of nucleic acid therapy and industrialization experts.

The company has established an industry-leading nucleiσc acid drug technology platform with proprietary intellectua★l property rights, including eSAFE chemical modification technol±ogy and STORK liver and extrahepatic delivery technology platforms. Based on the leadingα technology platforms, the company has rapidly developed a pipeline of small nucl≈eic acid drugs for antiviral, cardiovascular and metabolic diseases, autoimmune diseases, and cen™tral nervous system diseases. Two pipelines have entered the preclinical deve♥lopment stage.

The company is always patient-centered, committed to creating the  best small nucleic acid drugs, addressing unmet clinical needs, and enhancing human heaσlth and happiness.